Arena (ARNA) BELVIQ TRx Up 14% Last Week
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals (Nasdaq: ARNA) is about 2 percent lower on Friday's session following an update to BELVIQ prescriptions for the most recent week.
Bloomberg Industries, citing Symphony Data, said that total BELVIQ prescriptions rose 14 percent to 3,326 for the week ending July 19th. That's up from a previous count of 2,914 prescriptions.
It wasn't made clear what consensus estimates were at into the read.
Bloomberg Industries, citing Symphony Data, said that total BELVIQ prescriptions rose 14 percent to 3,326 for the week ending July 19th. That's up from a previous count of 2,914 prescriptions.
It wasn't made clear what consensus estimates were at into the read.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Genmab's Rina-S shows 45.9% response rate in ovarian cancer trial
- FDA approves Lilly's Jaypirca for first-line CLL/SLL treatment
- Arvinas to present ARV-102 Parkinson's trial data at MDS congress
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
